Publicly Listed Biopharma · Companies

Harbour BioMed, also known through its listed entity HBM Holdings, is a Hong Kong-listed biopharmaceutical company developing antibody-based therapeutics. Its technology platforms include the discovery of fully human antibodies, heavy-chain-only antibodies and additional engineered antibody formats. Oncology and immunology are important therapeutic areas. The company combines proprietary discovery activities with research partnerships and licensing arrangements. Its official website describes its antibody platform and identifies the Hong Kong listing. These antibody engineering capabilities support its oncology and immunology research strategy.

Innovent Biologics is a China-based biopharmaceutical company involved in research, development, manufacturing and commercialization of innovative medicines. Its technology base includes therapeutic antibodies and other protein-based medicines, with research across cancer, autoimmune diseases and cardiometabolic disorders. The company works with internal scientific teams and external partners to develop therapies and expand access to treatment. Innovent maintains an official corporate website and investor communications for its Hong Kong-listed issuer. Its principal approach brings biologic discovery together with clinical and commercial development.

Keymed Biosciences is a Hong Kong-listed biopharmaceutical company focused on discovering and developing novel therapeutic antibodies. Its research includes antibodies, multispecific formats and antibody-drug conjugates, with a focus on immune-mediated diseases, chronic conditions and cancers. The company has capabilities extending from early discovery through clinical development and works toward manufacturing and commercialization of selected treatments. Its website provides corporate information and descriptions of key technology platforms. Antibody engineering and immune disease research remain central to its scientific positioning.

Shanghai Fosun Pharmaceutical is a Chinese healthcare group with research, development, manufacturing and commercialization activities across pharmaceutical medicines and related healthcare businesses. Its innovative therapeutics work includes small-molecule drugs, biological medicines and collaborative development programs in oncology and other disease areas. The issuer is traded on both the Shanghai Stock Exchange and the Hong Kong Stock Exchange, which should be represented as two securities of a single listed group. Fosun Pharma also has businesses outside proprietary drug development, so the directory distinguishes its therapeutics activities from its wider corporate portfolio.

Shanghai Junshi Biosciences is a China-based innovative biopharmaceutical company focused on discovering and developing therapeutic antibodies and other medicines. Its work includes immuno-oncology, autoimmune and inflammatory diseases, as well as selected infectious-disease programs. The company is associated with the development of toripalimab, an anti-PD-1 antibody, and maintains broader research platforms for antibody engineering and targeted therapies. Junshi has shares listed on the Shanghai Stock Exchange STAR Market under 688180 and on the Hong Kong Stock Exchange under 1877. Both listings refer to the same issuer.

Bio-Thera Solutions is a China-based biopharmaceutical company developing innovative biologic therapies alongside biosimilar medicines. Its scientific work includes antibody therapeutics and other protein-based treatment approaches for serious diseases. The company emphasizes oncology, autoimmune diseases, cardiovascular conditions and selected additional therapeutic areas. Bio-Thera operates from Guangzhou, China, and its shares trade on the Shanghai Stock Exchange STAR Market under code 688177. Its inclusion reflects proprietary therapeutic research and development, not merely biosimilar distribution or contract manufacturing.

Mabwell is a China-based innovative biopharmaceutical company involved in discovering, developing, manufacturing and commercializing biologic medicines. Its scientific platforms include antibody discovery and engineering, as well as antibody-drug conjugate technologies. Research areas include oncology and immune-related disease. The company's official website identifies its Shanghai and Hong Kong stock codes and describes its integrated research and production capabilities. Both stock listings belong under the same issuer identity. The company integrates antibody platform research with pharmaceutical process and manufacturing capabilities.

Jiangsu Yahong Meditech, also known as Asieris Pharmaceuticals, is a Chinese biotechnology company developing therapeutics for oncology and related urologic conditions. Its work includes discovery, clinical development and commercialization-oriented research for serious diseases, with particular experience in drug candidates designed for specialized patient populations. The company is listed on the Shanghai Stock Exchange STAR Market under code 688176 and maintains corporate operations in China. This directory treats it as an innovative drug developer rather than a contract-service provider, while keeping its changing individual development programs outside the permanent profile.

Suzhou Zelgen Biopharmaceuticals is a Chinese innovative medicine developer headquartered in Kunshan, Jiangsu province. Its research and pharmaceutical development activities include small-molecule therapies and recombinant protein technologies, with an emphasis on cancers and selected additional diseases. The company conducts drug discovery, clinical research and product development with the objective of bringing proprietary therapeutics into medical use. Its shares are listed on the Shanghai Stock Exchange STAR Market under security code 688266.

Sinocelltech is a Chinese biopharmaceutical company engaged in developing, manufacturing and commercializing biological medicines. Its research activities include monoclonal antibodies, recombinant proteins and vaccines for diseases with significant medical needs. The corporate website identifies its Shanghai STAR Market listing and describes its research platforms, approved products and manufacturing capabilities. The company has worked across therapeutic as well as preventive biologic development. This directory emphasizes the company's issuer identity and long-term technical capabilities without maintaining a full inventory of changing clinical studies or product indications.

Betta Pharmaceuticals is a China-based innovative pharmaceutical company headquartered in Hangzhou, Zhejiang. Its operations span research, development, manufacturing and commercialization of prescription therapeutics, with strong historical emphasis on targeted cancer treatments. The company also pursues additional discovery technologies and external research collaborations to address unmet medical needs. Betta is listed on the Shenzhen Stock Exchange under security code 300558. Its drug development activities include small-molecule medicines and selected biologic collaborations.

Gan & Lee Pharmaceuticals is a listed Chinese pharmaceutical company specializing in medicines for diabetes and other metabolic diseases. It has extensive experience developing and manufacturing insulin products, including insulin analogues, and has expanded research into additional therapeutic areas. Its official corporate website displays the Shanghai stock code and describes its research, manufacturing and international business. The company's activities include both commercial pharmaceutical operations and continued drug development. Its research and manufacturing are anchored in therapies for diabetes and metabolic disorders.

Chengdu Kanghong Pharmaceutical Group is a listed Chinese pharmaceutical company engaged in the research, development, manufacture and sale of medicines. Its business includes biologic therapies, conventional small-molecule pharmaceutical products and traditional Chinese medicine activities. The company conducts innovative therapeutic research in ophthalmology, neurology and selected oncology areas while also operating established commercial medicine businesses. Kanghong is headquartered in Chengdu, Sichuan, and trades on the Shenzhen Stock Exchange under code 002773. Product-specific claims, regulatory changes and scientific updates are maintained through official company and exchange announcements.

Chongqing Zhifei Biological Products is a Chinese listed vaccine and biopharmaceutical developer engaged in vaccine research, development, manufacturing and commercialization. Its scientific activities include recombinant and other vaccine technologies, with work aimed at prevention of infectious diseases. The company combines proprietary development with external collaborations and licensed vaccine commercialization, requiring its original R&D activity to be distinguished from distribution-only operations. Zhifei is based in Chongqing, China, and its shares trade on the Shenzhen Stock Exchange under security code 300122.

Staidson is a Beijing-based biopharmaceutical company engaged in the research, development and commercialization of therapeutic medicines. Its development capabilities include biologic products and other pharmaceutical approaches for diseases with unmet treatment needs. A company-affiliated development program has disclosed research involving a therapeutic biological product for hemophilia, while the wider business includes established prescription medicines. Staidson trades on the Shenzhen Stock Exchange under stock code 300204. Its corporate website identifies the company's principal operating address in Beijing, and exchange filings support the issuer and listed-security information.

Walvax Biotechnology is a Chinese biotechnology company specializing in vaccine research, product development, manufacturing and commercialization. Its activities span immunization products and investigation of vaccine technologies for the prevention of infectious disease. The company operates an industrial and research platform in China and maintains a portfolio of marketed and investigational vaccines. Walvax is based in Kunming, Yunnan province, and its shares trade on the Shenzhen Stock Exchange under code 300142. Its inclusion is based on proprietary vaccine development rather than distribution or testing services alone.

CRISPR Therapeutics is a Swiss-incorporated biotechnology company developing medicines based on gene editing, including edited cell therapies and other genetic approaches. It uses CRISPR technology to investigate treatments for serious diseases, working across research, clinical development and commercialization partnerships. The corporate investor FAQ identifies Zug as its headquarters and Nasdaq ticker CRSP. Its official website and regulatory filings provide current information on its technologies, commercial arrangements and development programs. Genetic medicine and edited-cell technologies form the core of its therapeutic research.

GSK is a United Kingdom-based biopharmaceutical company that researches, develops, manufactures and commercializes specialty medicines and vaccines. Its therapeutic focus includes infectious diseases, immunology and oncology, using vaccine science and a range of medicinal approaches. The official investor website confirms London-listed ordinary shares and New York-listed American depositary shares under the GSK symbol; these are representations of one listed company. Its development work integrates vaccines, specialty medicines and research into immune-mediated diseases.

Immunocore Holdings is a United Kingdom-headquartered biotechnology company developing and commercializing T-cell receptor-based immunotherapies. Its platform uses engineered soluble T-cell receptors to engage immune mechanisms against targeted diseased cells. The company's therapeutic work includes oncology and investigational approaches for autoimmune and infectious diseases. Immunocore's shares trade on Nasdaq under IMCR, while the company's operational headquarters are in Oxfordshire, England. This concise profile records its technology and disease-area orientation rather than continually tracking the stages of individual programs.

Cellectis is a France-based biotechnology developer working on gene-edited cell therapies, including engineered T-cell approaches for cancer treatment. The company applies gene-editing technologies to develop therapeutic products and collaborates with partners in advancing these platforms. Its investor FAQ identifies ordinary shares on Euronext Growth Paris under ALCLS and American-listed securities on Nasdaq under CLLS, representing the same issuer across markets. A brief identity and technology overview is retained here, while clinical-program timing and partnership economics are left to its official investor and pipeline pages.

DBV Technologies is a France-based biopharmaceutical company developing epicutaneous immunotherapies for allergic conditions. Its technology is designed to deliver allergens through the skin to help modulate immune responses, with development efforts focused on food allergies and related diseases. DBV has research and clinical development activities aimed at evaluating this approach in patients with significant unmet needs. The company's ordinary shares trade on Euronext Paris under DBV, while American depositary shares trade on Nasdaq under DBVT. These are different securities linked to one issuer, not separate company records.

Nanobiotix is a French clinical-stage biotechnology company developing physics-based therapeutic approaches, including injectable nanoparticles intended to enhance local treatment effects when activated by radiotherapy. Its work targets cancers and aims to expand the potential of established radiation treatment through investigational nanomedicine technologies. The company has clinical research and development activities with external partners, and its programs remain subject to regulatory evaluation. Nanobiotix ordinary shares trade on Euronext Paris under NANO, and its American depositary shares trade on Nasdaq under NBTX.

Ascendis Pharma is a Danish biotechnology company developing treatments using its TransCon drug-development platform, which is designed to enable specific therapeutic delivery characteristics. Its programs include endocrine diseases and other serious conditions. The issuer announced an important security-structure change in April 2026: Nasdaq ticker ASND continued, but trading changed from American depositary shares to ordinary shares. This directory records the current security type rather than describing ASND as an ongoing ADS listing.

Genmab is a Denmark-based biotechnology company developing innovative antibody therapeutics through proprietary antibody-science platforms and collaborations. Its research emphasizes treatments for cancer and other serious diseases and extends from therapeutic discovery into clinical development and commercialization. Its official company pages describe multiple proprietary technologies, while its annual report documents the issuer across Nasdaq Copenhagen and the Nasdaq US market under GMAB. The directory treats the dual listings as one corporate entity.